Show simple item record

dc.contributor.authorLende, Tone Hoelen_US
dc.contributor.authorAustdal, Marieen_US
dc.contributor.authorVarhaugvik, Anne Elinen_US
dc.contributor.authorSkaland, Ivaren_US
dc.contributor.authorGudlaugsson, Einaren_US
dc.contributor.authorKvaløy, Jan Terjeen_US
dc.contributor.authorAkslen, Lars A.en_US
dc.contributor.authorSøiland, Håvarden_US
dc.contributor.authorJanssen, Emielen_US
dc.contributor.authorBaak, Jan P.A.en_US
dc.PublishedLende TH, Austdal M, Varhaugvik AE, Skaland I, Gudlaugsson E, Kvaløy JT, Akslen LA, Søiland H, Janssen EAM, Baak JPA. Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients - a randomized trial. BMC Cancer. 2019;19:1076eng
dc.description.abstractBackground: Conflicting results have been reported on the influence of carbohydrates in breast cancer. Objective: To determine the influence of pre-operative per-oral carbohydrate load on proliferation in breast tumors. Design: Randomized controlled trial. Setting: University hospital with primary and secondary care functions in South-West Norway. Patients: Sixty-one patients with operable breast cancer from a population-based cohort. Intervention: Per-oral carbohydrate load (preOp™) 18 and 2–4 h before surgery (n = 26) or standard pre-operative fasting with free consumption of tap water (n = 35). Measurements: The primary outcome was post-operative tumor proliferation measured by the mitotic activity index (MAI). The secondary outcomes were changes in the levels of serum insulin, insulin-c-peptide, glucose, IGF-1, and IGFBP3; patients’ well-being, and clinical outcome over a median follow-up of 88 months (range 33–97 months). Results: In the estrogen receptor (ER) positive subgroup (n = 50), high proliferation (MAI ≥ 10) occurred more often in the carbohydrate group (CH) than in the fasting group (p = 0.038). The CH group was more frequently progesterone receptor (PR) negative (p = 0.014). The CH group had a significant increase in insulin (+ 24.31 mIE/L, 95% CI 15.34 mIE/L to 33.27 mIE/L) and insulin c-peptide (+ 1.39 nM, 95% CI 1.03 nM to 1.77 nM), but reduced IGFBP3 levels (− 0.26 nM; 95% CI − 0.46 nM to − 0.051 nM) compared to the fasting group. CH-intervention ER-positive patients had poorer relapse-free survival (73%) than the fasting group (100%; p = 0.012; HR = 9.3, 95% CI, 1.1 to 77.7). In the ER-positive patients, only tumor size (p = 0.021; HR = 6.07, 95% CI 1.31 to 28.03) and the CH/fasting subgrouping (p = 0.040; HR = 9.30, 95% CI 1.11 to 77.82) had independent prognostic value. The adverse clinical outcome of carbohydrate loading occurred only in T2 patients with relapse-free survival of 100% in the fasting group vs. 33% in the CH group (p = 0.015; HR = inf). The CH group reported less pain on days 5 and 6 than the control group (p <  0.001) but otherwise exhibited no factors related to well-being. Limitation: Only applicable to T2 tumors in patients with ER-positive breast cancer. Conclusions: Pre-operative carbohydrate load increases proliferation and PR-negativity in ER-positive patients and worsens clinical outcome in ER-positive T2 patients.en_US
dc.rightsAttribution CC BYeng
dc.subjectBreast cancereng
dc.subjectCarbohydrate loadeng
dc.subjectInsulin c-peptideeng
dc.subjectTumor sizeeng
dc.subjectRelapse-free survivaleng
dc.subjectBreast cancer-specific survivaleng
dc.titleInfluence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients - a randomized trialen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Authors
dc.source.journalBMC Cancer

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY